|Indication & Dosage||Oral
Adult:Â 2 g daily.
|Administration||Should be taken on an empty stomach. Take on an
empty stomach between meals, preferably at bedtime at least 2 hr after food, milk, milk products or Ca supplements. Mix only w/ plain water & drink
|Special Precautions||Not recommended for use in patients with CrCl <30 ml/min. Patients at increased risk of venous thromboembolism.|
|Adverse Drug Reactions||Nausea and diarrhoea. Headache, loose stools and eczema. Transient reversible increases in creatine kinase activity.|
|Drug Interactions||Food, milk and derivative products, and medicinal products containing calcium may reduce the bioavailability of strontium ranelate. May
reduce the absorption of oral tetracycline and quinolone antibiotics.
Potentially Fatal:Â Food, milk and derivative products, and medicinal products containing calcium may reduce the bioavailability of strontium ranelate. May reduce the absorption of oral tetracycline and quinolone antibiotics.Â Please consult manufacturer's PIL (Prescribing Information Leaflet) for detailed drug interactions.
|Lab Interference||May interfere with determination of serum and urinary calcium.|
|Pharmacology||Strontium ranelate increases bone formation in
bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture. It also reduces bone resorption by decreasing
osteoclast differentiation and resorbing activity. This results in a rebalance of bone turnover in favour of bone formation.
Absorption:Â Oral bioavailability: about 25%. May be reduced by calcium or food.
Distribution:Â Low protein binding.
Metabolism:Â Not metabolised.
Excretion:Â Half-life: 60 hr. Excreted via kidneys and GI tract.
|ATC Classification||M05BX03 - strontium ranelate; Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.|